A recent US bill aimed at restricting WuXi AppTec and other Chinese biotech companies has been revised to allow more time for these entities to sever ties. The bill, which was initially proposed to limit collaborations between US research institutions and Chinese biotech firms due to national security concerns, has undergone changes to provide a grace period for compliance.
The revised bill acknowledges the complexity of disentangling partnerships and collaborations between US and Chinese entities in the biotech sector. It now includes provisions that outline a timeline for companies like WuXi AppTec to gradually phase out their connections with US institutions.
